Appeal No. 1997-1842
Application 08/068,878
peak and mean urinary flow rates improved by 49% and 36%, respectively. Page 1290,
column 1, last paragraph, through the column 2, second paragraph.
21. Dunzendorfer concluded that terazosin taken once-a-day offers benefits in
treating the symptoms of patients with BPH. Page 1291, column 1, third paragraph.
22. None of the references explicitly describe the administration of terazosin in
the treatment of BPH for a period of at least two and one-half years.
23. Fabricius shows that when BPH patients taking terazosin stop taking
terazosin, the beneficial effects of terazosin in the relief of symptoms of BPH were not
sustained.
24. Fabricius reported the results of a randomized, placebo-controlled, double-
blind study, where 10 mg/day of terazosin was given to fifty-seven patients with BPH.
After a four-week placebo lead-in and a 24-week treatment period (the single-blind
phase) with terazosin, thirty patients who responded to terazosin were randomly
assigned either to be given terazosin or a placebo for twelve weeks (double-blind
phase). Fabricius, page 86, line 14, to page 87, line 6.
25. During the single-blind treatment period, the peak urine flow rate increased
54%, after terazosin treatment. The mean flow rate increased 55%. The mean
obstructive symptom score and irritative symptom source improved 68% and 34%,
respectively. Fabricius, Table 1, and the accompanying text.
12
Page: Previous 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next
Last modified: November 3, 2007